New Drugs in Hematology

Transcription

1 New Drugs in Hematology Bologna, Royal Hotel Carlton, May 9-11, 2016 PROGRAM Monday, May 9, am Welcome and Introduction Three recent impressive stories Chairman: F. Pane 9.15 am Brentuximab vedotin in lymphomas A. Younes 9.45 am Blinatumumab in ALL M.S. Topp am CAR T-cells C.H. June am Coffee Break SESSION I: Classical Ph1-neg myeloproliferative neoplasms Chairmen: F. Passamonti, A.M. Vannucchi am Status of the art of treatment R.A. Mesa am Ruxolitinib in myelofibrosis F. Passamonti am Ruxolitinib in polycitemia vera A.M. Vannucchi am New JAK2 inhibitors in MPNs and combination therapy F. Cervantes pm Interferons in MPNs H.C. Hasselbalch pm Newer drugs for myelofibrosis G. Barosi pm LUNCH SESSION II: Hodgkin s lymphoma Chairmen: P. Borchman, P.L. Zinzani 1.45 pm Status of the art of treatment P. Borchman 2.10 pm Nivolumab A. Younes 2.25 pm Pembrolizumab S. Schuster 2.40 pm Bendamustine A. Moskowitz 2.55 pm New Combo-steps A. Younes

2 SESSION III: Chronic myeloid leukemia Chairmen: M. Gobbi, G. Rosti 3.30 pm Status of the art of treatment M. Baccarani 3.55 pm Nilotinib-based treatments and ABL001 G. Rosti 4.15 pm Dasatinib and combination G. Saglio 4.30 pm Bosutinib T.H. Brummendorf 4.45 pm Ponatinib G. Rosti Tuesday, May 10, 2016 Two transversal on lymphomas drugs Chairman: P. Corradini 8.30 am Bendamustine B. Cheson 9.00 am - Lenalidomide T. Witzig SESSION IV: Non-Hodgkin s lymphoma (I) Chairmen: B. Cheson, A. Pinto 9.15 am Status of the art of treatment B. Cheson 9.40 am Obinutuzumab L.H. Sehn 9.55 am Ublituximab N. Fowler am MOR208 P.L. Zinzani am anti-4-1bb A. Thall am Polatuzumab F. Morschhauser am Mogamulizumab M. Ogura am 177Lu-HH1 (Betalutin) A. Kolstad am CC-122 V. Ribrag am EDO-S101 O. O Connor pm IMGN529 A. Stathis pm Selinexor S. Shacham pm Pixantrone R. Pettengell LUNCH

3 SESSION V: Non-Hodgkin s lymphoma (II) Chairmen: U. Vitolo, M. Martelli 2.00 pm Venetoclax S. Rule 2.15 pm Idelalisib S. de Vos 2.30 pm Ibrutinib M. Wang 2.45 pm TGR-1202 O. O Connor 3.00 pm Copanlisib M. Dreyling 3.15 pm Duvelisib N. Fowler 3.30 pm ACP-196 S. LeGouill 3.45 pm Tazemetostat V. Ribrag SESSION VI: Chronic Lymphocitic Leukemia Chairmen: R. Foà, A. Cuneo 4.15 pm Status of the art of management S. O Brien 4.45 pm Ibrutinib J.A. Burger 5.00 pm Idelalisib S. Coutre 5.15 pm Venetoclax P. Hillmen 5.30 pm ACP-196 S. O Brien 5.45 pm Duvelisib P. Porcu 6.00 pm TGR-1202 and Ublituximab A. Mato Wednesday, May 11, 2016 Other two interesting issues Chairman: A. Genazzani, P.L. Zinzani 8.30 am - Rituximab biosimilars P.L. Canonico, M. Peters 9.00 am The role of liposomal doxorubicin in DLBCL lymphomas M. Spina SESSION VII: Acute leukemia Chairmen: S. Amadori, G. Martinelli 9.30 am Status of the art of treatment H. Dohner 9.55 am Targeting BET in acute myeloid leukemia B. Huntly am IDH2 inhibitors in acute myeloid leukaemia E. M. Stein am FLT3 inhibitors in acute myeloid leukaemia R.M. Stone

4 10.40 am Inotuzumab ozogamicin in acute lymphoblastic leukaemia H. Kantarjian am BCR-ABL like in acute lymphoblastic leukaemia I. Iacobucci am The role of RO in acute myeloid leukaemia G. Martinelli SESSION VIII: Multiple myeloma Chairmen: M. Cavo, S. Lonial am Status of the art of treatment A. Palumbo am Modeling of disease evolution: what have we learned and how can we drive future treatment strategies? G. Morgan pm New insights into optimal use of PIs and IMiDs based on sensitizing targets and biomarkers P. Moreau pm Histone deacetilase and kinase inhibitors S. Lonial pm Monoclonal antibodies and their integration into the modern therapeutic algorithms M. Cavo pm Immune checkpoint inhibitors and immune-based therapies P. Richardson 1.05 pm Is personalized therapy ready for primetime? S.K. Kumar 1.20 pm Conclusions and Arrivederci

5 GENERAL INFORMATION MEETING VENUE Royal Hotel Carlton Via Montebello, Bologna, Italy Phone HOW TO GET THERE By car : From the motorway, turn into the ring road ("Tangenziale") - Exit 7 Fiera and follow direction city center and railway station. By taxi: From the airport about 30 minutes. By bus: Bus 91 and Aerobus from the airport. By train: From the railway station walking distance. OFFICIAL LANGUAGE English. REGISTRATION FEE Euro 400,00 (Italian VAT included) The registration fee includes: Conference kit Participation in the scientific sessions Attendance Certificate Abstracts of the meeting Coffee breaks Lunches SLIDES Slides must be in English. Computer video projection will be available in Power Point. Other requirements should be communicated to the Organizing Secretariat as soon as possible. Slides should be handed to the slide center one hour before the beginning of the session and collected at the end. BADGE All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions. ATTENDANCE CERTIFICATE A certificate will be given to all participants at the end of the Meeting. ITALIAN AND EUROPEAN CME Application to the Italian Ministry of Health and the European Board for Accreditation in Hematology (EBAH) will be submitted for physicians, biologists and chemists. CHANGES Parts of the program may be changed if necessary.